Cryolife Inc  

(Public, NYSE:CRY)   Watch this stock  
Find more results for CRY
5.41
-0.15 (-2.70%)
Real-time:   12:09PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 5.37 - 5.55
52 week 4.00 - 6.02
Open 5.55
Vol / Avg. 16,595.00/69,607.00
Mkt cap 149.07M
P/E 18.17
Div/yield     -
EPS 0.30
Shares 27.55M
Beta 0.96
Inst. own 56%
Jul 31, 2012
Q2 2012 CryoLife, Inc. Earnings Conference Call - Webcast
May 31, 2012
CryoLife, Inc. at Benchmark Investor One-on-One Conference
May 16, 2012
CryoLife, Inc. Annual Shareholder Meeting
May 15, 2012
CryoLife, Inc to Acquire Hemosphere, Inc - Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '12) 2011
Net profit margin 10.05% 6.16%
Operating margin 17.57% 9.73%
EBITD margin - 13.88%
Return on average assets - 5.17%
Return on average equity - 6.13%
Employees 430 -
Carbon Disclosure Rating - -

Address

1655 Roberts Blvd NW
KENNESAW, GA 30144
United States - Map
+1-770-4193355 (Phone)
+1-770-9529743 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

CryoLife, Inc. (CryoLife,) is a biological medical device company. The Company preserves and distributes human tissues for transplantation and develops, manufactures, and commercializes medical devices for cardiac and vascular applications. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve (CryoValve SGPV) and the CryoPatch SG pulmonary cardiac patch tissue (CryoPatch SG), both processed using CryoLife�s SynerGraft technology. The Company operates in two segments: preservation services and medical devices segment. In May 2011, it acquired Cardiogenesis Corporation. In May 2012, the Company acquired Hemosphere, Inc. Hemosphere develops and markets the HeRO (Hemodialysis Reliable Outflow) Graft, a graft-based solution for end-stage renal disease (ESRD) hemodialysis patients with limited access options and central venous obstruction.

Officers and directors

Steven G. Anderson Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation - Reuters
D. Ashley Lee CPA Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 47
Bio & Compensation - Reuters
Gerald B. Seery Senior Vice President - Sales and Marketing
Age: 55
Bio & Compensation - Reuters
Jeffrey W. Burris Vice President, General Counsel
Age: 40
Bio & Compensation - Reuters
Scott B. Capps Vice President - Clinical Research
Age: 45
Bio & Compensation - Reuters
David M. Fronk Vice President - Regulatory Affairs and Quality Assurance
Age: 48
Bio & Compensation - Reuters
David C. Gale Ph.D. Vice President - Research & Development
Age: 44
Bio & Compensation - Reuters
Jon W. Salveson Director
Age: 45
Bio & Compensation - Reuters
Thomas F. Ackerman Independent Director
Age: 57
Bio & Compensation - Reuters
James S. Benson Independent Director
Age: 73
Bio & Compensation - Reuters